The company plans to expand access to its Prevanar 13 vaccine in humanitarian emergency settings.
In a Nov. 11, 2016 press release Pfizer said that the company will be expanding its humanitarian assistance program allowing for broader access to the Prevenar 13 vaccine in humanitarian emergency settings. In situations where there is a need for humanitarian aid, Prevenar 13, a pneumococcal conjugate vaccine, will now be offered in a multi-dose vial for $3.10 per dose. During the first year of the expanded program, Pfizer said it will be donating all sales proceeds to humanitarian groups.
Refugees will be able to receive the multi-dose vial version of Prevenar 13 starting in 2017, Pfizer said in a statement. The new vial contains four doses of the vaccine and is scheduled to be introduced early next year. The multi-dose vial is the same size as the single-dose version and offers reduced cold storage and transportation requirements. This new version of Prevanar 13 has been prequalified by the World Health Organization.
In the immediate term, Pfizer said it will meet humanitarian emergency needs through a short-term donation of the single-dose vial of Prevenar 13, which is available for expedited delivery. In a statement, Susan Silbermann, president and general manager of Pfizer Vaccines, said the company is “proud of the significant impact that our Prevenar 13 vaccine and our partnerships with many humanitarian organizations have had on public health across the globe.”
Source: Pfizer
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.